NYSE Content Advisory: Pre-Market Update + ICE Data Show Home Affordability at Nearly Three-Year High
NEW YORK, Dec. 8, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…
iScreen Widget Adds Customizable Snow Globe Widget in Christmas-Themed Update for iOS 26 and Android
Holiday update adds interactive widgets, themed layouts, and seasonal wallpapers for device customization. LOS ANGELES, Dec. 8, 2025 /PRNewswire/ — iScreen,…
Acer Reports Revenues for November at NT$24.60 Billion with Growth of 15.9% Month-on-month and 8.1% Year-on-year
TAIPEI, Dec. 8, 2025 /PRNewswire/ — Acer Inc. (TWSE: 2353) announced its consolidated revenues for November at NT$24.60 billion, up…
Sennics Unveils Major Breakthroughs in New Eco-Friendly Antioxidant SA6000
SHANGHAI, Dec. 8, 2025 /PRNewswire/ — On December 8, 2025, to commemorate the second anniversary of the Seminar on Future…
SJTU International Gen Z Students Explore Shanghai’s Innovation Ecosystem
SHANGHAI, Dec. 8, 2025 /PRNewswire/ — Shanghai Jiao Tong University’s Antai Global Summer Program (AGSP) welcomed a diverse cohort of…
CIMC Unveils New Global Brand Logo and Visual Identity System
SHENZHEN, China, Dec. 7, 2025 /PRNewswire/ — On December 5, 2025, China International Marine Containers (Group) Co., Ltd. (CIMC) unveiled…
Median PFS Trending Beyond One Year: Leads Biolabs’ LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
NANJING, China, Dec. 7, 2025 /PRNewswire/ — From December 6 to 9, 2025, the 67th Annual Meeting of the American…
IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
SHANGHAI and NANJING, China and PLEASANTON, Calif., Dec. 7, 2025 /PRNewswire/ — IASO Biotechnology (“IASO Bio”), a commercial-stage biopharmaceutical company…
Lilly’s Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved…
Replicor publishes data from its compassionate access program in HBV/HDV
MONTREAL, Dec. 7, 2025 /PRNewswire/ – Replicor Inc. announced the publication of data from its first global compassionate access program…
↑